Lumosa’s LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trials

Lumosa Therapeutics has reported positive findings from two Phase II studies evaluating its small molecule–peptide conjugate odatroltide (LT3001) in acute ischemic stroke (AIS).

In the China-based LT3001-202 trial (NCT05686642), odatroltide improved modified Rankin Scale (mRS) 0–1 and 0–2 outcomes by 8% and 13% over placebo in moderate AIS patients with disabling symptoms. Benefits were also observed in patients with large-artery atherosclerosis and in mismatch-positive subgroups.

The Phase II BRIGHT study (NCT05403866) showed that 27% of treated patients achieved mRS 0–1 versus 17% with placebo. Both trials enrolled patients within 24 hours of stroke onset, extending beyond standard thrombolysis windows. No increase in symptomatic intracranial haemorrhage was reported.

LT3001 combines thrombolytic and neuroprotective mechanisms. It enters a competitive field that includes Genentech’s TNKase and Activase, as well as late-stage candidates such as Bayer’s asundexian.

17-02-2026